Arnold Palmer fronts Centocor, Us TOO prostate cancer website

Share this article:
Arnold Palmer fronts Centocor, Us TOO prostate cancer website
Arnold Palmer fronts Centocor, Us TOO prostate cancer website

Golf legend and prostate cancer survivor Arnold Palmer is the celebrity face of a new educational website and program developed by Centocor Ortho Biotech and Us TOO, a nonprofit prostate cancer support organization.

Located at MyProstateCancerRoadmap.com, the website – targeted at men with advanced prostate cancer and their caregivers – provides information around topic areas like work, relationships, sex and intimacy, and high-risk populations. In the resources section, the site offers links to non-profit and advocacy organizations, downloadable questions about nutrition and exercise to be asked in the doctor's office, and other tips. The website, which launched today, currently has a few kinks, and the resources for download currently link to pages of indecipherable code, instead of question lists and exercise tips.  

The site is unbranded and “excludes marketing of any kind,” in keeping with Us TOO policy and National Health Council guidelines, said Tom Kirk, president and CEO at Us TOO. “We have final review over any of the materials [on the site],” said Kirk. After registering, users can expect “ongoing email messages on specific topics related to prostate cancer,” Kirk said.    

Lisa Vega, a spokesperson for Centocor, said the website launch coincides with the first day of Prostate Cancer Awareness month. The site will be promoted through Us TOO members and affiliated groups, and follows a satellite media tour this morning that featured Us TOO chairman Fred Mills and Arnold Palmer, which aired on TV, as well as radio news and sports stations, according to an Us TOO announcement. According to Vega, the website and program will be updated with “new information, articles from experts and other resources including webcasts, podcasts and other vehicles.” The site also features a testimonial area where users are encouraged to submit stories for a chance to win Blue Ribbon Recipes for Prostate Health, a cookbook. Vega declined to name the agency that built the website.

Centocor Ortho Biotech, a division of Johnson & Johnson, doesn't “currently market any treatments for prostate cancer,” said Vega. Ortho Biotech Oncology Research and Development, and affiliate of Centocor, is currently in phase 3 trials with abiraterone acetate, an investigational oral androgen biosynthesis inhibitor, for the treatment of metastatic advanced prostate cancer, Vega said.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...